Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress
September 08 2024 - 6:05PM
8
September 2024
Avacta Group plc
(“Avacta” or “the Group” or “the Company”)
Avacta to present updated clinical data
on AVA6000 at the European Society for Medical Oncology (ESMO)
Congress
Avacta Group plc (AIM: AVCT), a life sciences company developing
innovative, targeted cancer treatments and powerful diagnostics,
today announces that the company will present updated data from the
Phase 1a trial of AVA6000 at the 2024 European Society for Medical
Oncology (ESMO) Congress, in Barcelona, Spain from 13-17 September
2024.
The poster presentation will be based on an updated data cut
from the Phase 1a trial of AVA6000 in patients with Fibroblast
Activation Protein (FAP)-positive solid tumours. AVA6000 is a
peptide drug conjugate consisting of doxorubicin conjugated with a
peptide moiety that is specifically cleaved by FAP in the tumour
microenvironment.
Abstract details are listed below and available online on the
ESMO website.
Title: A Phase I trial of AVA6000, a Fibroblast
Activation Protein (FAP)-released, tumour microenvironment
(TME)-targeted doxorubicin peptide drug conjugate in patients with
FAP-positive solid tumours Session Title:
Developmental therapeutics Session Date and Time:
Saturday, September 14, 2024, 9AM CEST
time.Location: Fira Barcelona Gran Via Av. Joan
Carles, Barcelona, SpainAbstract Presentation
Number: 646P First Author: Professor
Chris Twelves, University of Leeds
-Ends-
For further information from Avacta
Group plc, please contact:
|
Avacta Group plcChristina Coughlin, CEOMichael
Vinegrad, Group CommunicationsDirector |
Tel: +44 (0) 1904 21 7070www.avacta.com |
|
|
|
|
Peel Hunt (Nomad and Broker)James Steel / Chris
Golden / Patrick Birkholm |
www.peelhunt.com |
|
ICR ConsiliumMary-Jane Elliott / Jessica Hodgson /
Sukaina Virji |
avacta@consilium-comms.com |
About Avacta Group plc
- www.avacta.com
Avacta Group is a UK-based life sciences
company focused on improving healthcare outcomes through targeted
cancer treatments and diagnostics.
Avacta Therapeutics: a clinical stage oncology
biotech division harnessing proprietary therapeutic platforms to
develop novel, highly targeted cancer drugs.
Avacta Diagnostics focuses on supporting
healthcare professionals and broadening access to diagnostics.
Avacta has two proprietary platforms,
pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly specific
substrate for fibroblast activation protein (FAP) which is
upregulated in most solid tumours compared with healthy tissues.
The pre|CISION™ platform harnesses this tumour specific protease to
activate pre|CISION™ peptide drug conjugates and pre|CISION™
antibody/Affimer® drug conjugates in the tumour microenvironment,
reducing systemic exposure and toxicity, allowing dosing to be
optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme AVA6000, a
peptide drug conjugate form of doxorubicin, is in Phase 1 studies.
It has shown an improvement in safety and tolerability in clinical
trials to date compared with standard doxorubicin and preliminary
signs of clinical activity in multiple patients.
To register for news alerts by email go
to www.avacta.com/investor-news-email-alerts
Avacta (LSE:AVCT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Nov 2023 to Nov 2024
